VivoSeq
Infectious Disease

COVID-19

1.4K

Pipeline Programs↗

126

Active Trials↗

331

Companies Involved↗

COVID-19 is a highly competitive landscape with 1449 programs across 331 companies. The most active players are Suzhou Abogen Biosciences Co., Ltd., Beijing Minhai Biotechnology Co., Ltd, Emergent BioSolutions. 158 therapies are approved with 402 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

55/100

Mech. Concentration

6/100

Completion Rate

68/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Suzhou Abogen Biosciences Co., Ltd.

2 programs

Phase 1B

Beijing Minhai Biotechnology Co., Ltd

2 programs

Phase 1Emergent BioSolutions logo

Emergent BioSolutions

2 programs

Phase 1W

Walvax Biotechnology Co., Ltd.

1 program

Phase 1E

Everest Medicines (Singapore) Pte. Ltd.

1 program

Phase 1R

Ridgeback Biotherapeutics, LP

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

1,112 of 1,472 classified programs — the dominant modality here.

24%ALL OTHERSVaccine24216%Monoclonal antibody483%RNA therapy252%Cell therapy221%Protein / enzyme191%Peptide4<1%

Small molecule leads; the ring shows all 1,472 classified programs, each share of the total. Modality classified for 100% of 1,932 pipeline programs.

Analysis

Trial Status

2,676

clinical trials

Completed1,263 · 47%
Unknown status658 · 25%
Terminated366 · 14%
Withdrawn214 · 8%
Recruiting55 · 2%
Active, not recruiting50 · 2%
Other70 · 3%

Clinical Trials

Trial Activity

2676 trials

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
Recruiting·MModeX Therapeutics, An OPKO Health Company·Phase 1·NCT07445971·80 enrolled
Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment
Recruiting·—·Phase 2·NCT06159283·58 enrolled
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Recruiting·CCardresearch·Phase 3·NCT04727424·7,819 enrolled
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
Recruiting·TTraws Pharma, Inc.·Phase 2·NCT07157007·90 enrolled
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Recruiting·Pfizer logoPfizer·Phase 3·NCT05261139·160 enrolled
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
Recruiting·CCastleVax Inc.·Phase 2·NCT07215520·200 enrolled
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
Recruiting·RRokote Laboratories Finland Oy·Phase 1·NCT07416539·20 enrolled
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
Recruiting·AANRS, Emerging Infectious Diseases·Phase 1/2·NCT06255626·215 enrolled
Randomised Evaluation of COVID-19 Therapy
Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Recruiting·SStanford University·N/A·NCT04579588·230 enrolled
A Study to Examine Anktiva for the Treatment of COVID-19.
Recruiting·IImmunityBio, Inc.·Phase 2·NCT07123727·40 enrolled
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT06599658·660 enrolled
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
Recruiting·—·Phase 2·NCT07406217·256 enrolled
Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
Recruiting·CCode Pharma·Phase 2·NCT05218356·130 enrolled
COVID-19 Vaccines Safety Tracking (CoVaST)
Recruiting·MMasaryk University·N/A·NCT04834869·30,000 enrolled
Page 1 of 179

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)